This approval allows the use of Durvalumab in combination with Tremelimumab, broadening treatment options for patients ...

Goldman Sachs analysts added AstraZeneca (AZN) to the firm’s European Conviction List as part of its monthly update. With 28 Phase-3 readouts ...

The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

AstraZeneca has opened a plant to produce biogas from organic waste that will ensure by the end of this year all of its ...

The results showed statistically significant and clinically meaningful improvement in progression-free survival compared with ...

Investment analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for shares of AstraZeneca in a report issued on Thursday, February 27th. Zacks Research analyst R.

Drugmaker AstraZeneca on Wednesday said that its experimental breast cancer treatment improved patient survival without the ...

AstraZeneca has advanced its push to make camizestrant a blockbuster, reporting a phase 3 win for the oral SERD at an interim ...

Amgen (AMGN) and AstraZeneca (AZN) announced full results from the Phase 3, registrational WAYPOINT trial demonstrating that TEZSPIRE ...

Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...

The Phase III SERENA-6 trial is the first global trial to use a circulating tumor DNA-guided approach to detect endocrine ...

AstraZeneca Pharma India has received approval from CDSCO to import and distribute the cancer treatment drug Durvalumab ...